Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$2.06 | -$2.06 | -$2.06 |
Q2 2024 | 1 | -$1.15 | -$1.15 | -$1.15 |
Q3 2024 | 2 | -$1.18 | $3.53 | $1.47 |
Q4 2024 | 1 | $4.22 | $4.22 | $4.22 |
Q1 2025 | 1 | $3.39 | $3.39 | $3.39 |
Q2 2025 | 1 | $4.12 | $4.12 | $4.12 |
Q3 2025 | 1 | $4.46 | $4.46 | $4.46 |
Q4 2025 | 1 | $4.68 | $4.68 | $4.68 |
Calliditas Therapeutics AB (publ) last posted its earnings results on Monday, November 11th, 2024. The company reported $-0.58 earnings per share for the quarter, missing analysts' consensus estimates of $-0.22 by $0.36. The company had revenue of 559.78 M for the quarter and had revenue of 1.21 B for the year. Calliditas Therapeutics AB (publ) has generated $-9 earnings per share over the last year ($-8.69 diluted earnings per share) and currently has a price-to-earnings ratio of -23.25. Calliditas Therapeutics AB (publ) has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 10th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/13/2024 | Q2 2024 | -$0.13 | -$0.88 | -0.75 | $454.87 M | $559.78 M |
04/25/2024 | Q1 2024 | -$9.17 | $295.48 M | |||
04/24/2024 | Q4 2023 | -$0.34 | $451.56 M | |||
09/29/2023 | Q3 2023 | -$3.14 | $325.21 M | $294.59 M | ||
08/17/2023 | Q2 2023 | -$0.25 | -$1.71 | -1.46 | $292.22 M | $269.38 M |
04/28/2023 | Q1 2023 | -$3.49 | $191.35 M | |||
04/26/2023 | Q4 2022 | -$0.07 | $429.04 M | |||
09/29/2022 | Q3 2022 | -$0.34 | $132.95 M | $260.06 M | ||
04/29/2022 | Q2 2022 | -$7.24 | $80.21 M | $64.05 M | ||
04/29/2022 | Q1 2022 | -$7.91 | $49.73 M | |||
04/27/2022 | Q4 2021 | -$8.37 | $31.18 M | |||
09/29/2021 | Q3 2021 | $0.25 | $198.17 M | |||
06/29/2021 | Q2 2021 | -$6.40 | $0 | |||
03/30/2021 | Q1 2021 | -$5.02 | $0 | |||
04/27/2021 | Q4 2020 | -$6.83 | $400,000 | |||
09/29/2020 | Q3 2020 | -$5.54 | $0 | |||
06/29/2020 | Q2 2020 | -$3.00 | $0 | |||
03/30/2020 | Q1 2020 | -$3.29 | $474,000 | |||
12/30/2019 | Q4 2019 | -$0.60 | $46.59 M | |||
09/29/2019 | Q3 2019 | -$2.60 | $0 |
Calliditas Therapeutics AB (publ) has not confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 10th, 2024 based off last year's report dates.
The conference call for Calliditas Therapeutics AB (publ)'s latest earnings report can be listened to online.
The conference call transcript for Calliditas Therapeutics AB (publ)'s latest earnings report can be read online.
Calliditas Therapeutics AB (publ) (:CALT) has a recorded annual revenue of $1.21 B.
Calliditas Therapeutics AB (publ) (:CALT) has a recorded net income of $1.21 B. Calliditas Therapeutics AB (publ) has generated $-8.69 earnings per share over the last four quarters.
Calliditas Therapeutics AB (publ) (:CALT) has a price-to-earnings ratio of -23.25 and price/earnings-to-growth ratio is -2.74.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED